Vertex Pharmaceuticals (VRTX) reached an agreement Wednesday with the Food and Drug Administration that shaves nine months off the length of its next pivotal cystic fibrosis clinical trial.
The speedy trial design means the first of Vertex’s three-drug regimens for cystic fibrosis could have top-line results by the end of this year or early in 2019 — faster than anticipated. The company’s accelerated timeline also makes it harder for any of its cystic fibrosis competitors to keep pace.
About the Author Reprints
